Needham & Company Reiterates Buy Rating on Sage Therapeutics (SAGE), Analysts Expects no Impact on Stock From the Recent Earning Readout
Go back to Needham & Company Reiterates Buy Rating on Sage Therapeutics (SAGE), Analysts Expects no Impact on Stock From the Recent Earning Readout| Sagebrush Gold Ltd. (NASDAQ: SAGE) | Delayed: 13.01 +0.12 (0.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $12.89 | 52 Week High | $62.64 | |||
| Open | $12.91 | 52 Week Low | $26.28 | |||
| Day High | $13.38 | P/E | N/A | |||
| Day Low | $12.74 | EPS | $-0.94 | |||
| Volume | 167,075 | |||||
